when do you start feeling the side effects of semaglutide Patel it Like it is: long-term taking When Do Semaglutide Side Effects

Indications: Type 2 Diabetes Mellitus (monotherapy or add-on therapy) Especially useful in patients who cannot tolerate metformin or sulfonylureas Can be used in elderly and patients with mild renal impairment Approved Agents in India: Sitagliptin (Januvia) Vildagliptin (Galvus) Saxagliptin (Onglyza) Linagliptin (Trajenta) No renal dose adjustment needed Alogliptin (Nesina) Dosing: Once daily oral dosing Some agents require renal dose adjustment (except Linagliptin) Often combined with metformin or SGLT2 inhibitors Side Effects: Nasopharyngitis, headache GI upset (mild) Rare: Acute pancreatitis, severe joint pain, skin reactions Saxagliptin may slightly increase risk of heart failure in some patients Advantages Over Other Classes: Weight neutral Low risk of hypoglycemia Well tolerated in the elderly Convenient once-daily dosing Limitations: Modest HbA1c reduction (0.50.8%) Not effective in Type 1 Diabetes Less potent than GLP-1 analogs or SGLT2 inhibitors Conclusion: DPP-4 inhibitors are a safe, effective, and well-tolerated option for many patients with T2DM especially those needing an add-on to metformin or who can't tolerate injectables

however, there is little information on effects on other pancreatic tissues that might be involved in inflammatory processes

Metformin dosage for fatty liver: Learn why metformin isn't approved for MASLD, what the evidence shows, and how standard diabetes dosing applies when patients have coexisting fatty liver disease.

GLP-1 and Steroids: Same Story, Different Era

Seventy-two week outcomes from the SURMOUNT-5 clinical trial have shown that tirzepatide (Zepbound) met the primary endpoint and all five key secondary endpoints, demonstrating superiority, compared to semaglutide (Wegovy) across the trial.The detailed results were presented at the 32nd European Congress on Obesity (ECO) and simultaneously published in The New England Journal of Medicine.SURMOUNT-5 was a 72-week, multi-centre, randomised, open-label, Phase 3b trial evaluating the efficacy and